We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

By LabMedica International staff writers
Posted on 02 Dec 2021
Print article
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)
Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.

Around 870 cases of ovarian cancer (OV) are reported in Belgium every year and 600,000 worldwide. Most of these patients are treated with surgical interventions and/or chemotherapy. Molecule-specific therapy or immunotherapy are some of the latest approaches that have been investigated recently for ovarian cancer treatment, but with no major breakthroughs in overcoming this challenging disease.

An international team of clinical scientists led by those at the Katholieke Universiteit Leuven (Leuven, Belgium) used a data-driven in silico framework, integrating existing tumor/blood bulk-RNAseq or single-cell (sc)RNAseq datasets of patients with cancer, to inform the design of an innovative serum-screening modality, that is, serum-functional immunodynamic status (sFIS) assay. Next, they pursued proof-of-concept analyses via multiparametric serum profiling of patients with OV with sFIS assay combined with Luminex cytokines/soluble immune checkpoints (Luminex Corp, Austin, TX, USA), CA125-antigen detection, and whole-blood immune cell counts.

Customized Procartaplex Immunoassays Kits (Life Technologies, Merelbeke, Belgium) were used to determine IL10, IFNα, IL12p70, LAG3, IL6, IDO1, PGF, Arginase, PD-L1, IFNγ, PD1, CXCL10, CCL2, CCL11, CCL22, VEGF-A, TIM3, CCL5, MMP9, and LAP/TGFβ. The sFIS assay’s ability to determine survival benefit or malignancy risk was validated in a discovery (n=32) and/or validation (n=699) patient cohorts. The sFIS assay was standardized and absorbance was examined at an optical density of 655 nm, 4–8 hours after Quanti-Blue addition by microplate reader (Biotek, Winooski, VT, USA).

The investigators reported that multiparametric serum profiling of patients with OV established that sFIS assay can: decode peripheral immunology by indicating higher enrichment of serum-induced (si)-NFκB over si-interferon/interferon-stimulated genes (si-IFN/ISG) responses; estimate survival trends (si-NFκB or si-IFN/ISG responses associating with negative or positive prognosis, respectively; and coestimate malignancy risk relative to benign/borderline ovarian lesions. Biologically, they documented dominance of pro-tumorigenic, myeloid si-NFκB responseHIGHsi-IFN/ISG responseLOW inflammation in periphery of patients with OV.

Abhishek D. Garg, MBBS, MD, DNB, a professor and a lead author of the study said, “Our team wanted to capture the real rhythms or fluctuations of treatment or survival-relevant pathways, and hence we went in search of personalized, dynamic biomarkers that determine patients' chances of survival. The sFIS assay strategy has been applied for the first time with ovarian cancer, but will also be tested in other types of cancer.”

The authors concluded that their sFIS assay may facilitate personalized patient monitoring, immunostratification and immunotherapeutic decision-making. The differential si-NFκB or si-IFN/ISG response can shed light on how the peripheral immune responses are regulated or dysregulated. The study serves as a proof of concept for further clinical development of peripheral immunodynamic biomarkers. The study was published on November 18, 2021 in the Journal for ImmunoTherapy of Cancer.

Related Links:
KU Leuven
Luminex Corp
Life Technologies
Biotek


New
Gold Supplier
Benchtop Real-Time PCR Analyzer
Savanna
New
Automated R-AST Solution
Radian BC
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
3-Part Diff Hematology Analyzer
DLB3

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.